Tectonic enters public markets in one of few biotech reverse mergers this year

Kyle LaHucik

Senior Reporter

Tectonic Therapeutic, a biotech from renowned entrepreneur and researcher Tim Springer, completed its reverse merger with gene therapy company Avrobio on Thursday …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Tectonic enters public markets in one of few biotech reverse mergers this year

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Associate Director, Market Insights and Analytics

Celldex Therapeutics

Hampton, NJ, USA

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

FDA rejects Daiichi Sankyo's HER3 ADC, a blow to quick approval plans for Merck partnership

Maze spins its ALS antisense program into a secretive new company

AbbVie buys Third Rock's Celsius for $250M to expand IBD pipeline

Exclusive: To develop better cell therapies for solid tumors, a new startup plans to test hundreds of them at once

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Tec­ton­ic en­ters pub­lic mar­kets in one of few biotech re­verse merg­ers this year

Senior Reporter

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

Tectonic enters public markets in one of few biotech reverse mergers this year